Parabilis Medicines PBLS 深 滬
已收盤 11-06 16:00:00 美东时间
28.53
+0.650
+2.33%
華盛通- 最 高28.87
- 今 開27.88
- 成交量 62.93万股
- 最 低 27.11
- 昨 收 27.88
- 總市值 352.44万
- 52周最高 42.485
- 市盈率 靜 --
- 換手率 0.51%
- 52周最低 22.66
- 委 比 79.08%
- 總股本 0.00亿
- 歷史最高 42.485
- 量 比 0.83
- 振 幅 6.31%
- 歷史最低 22.66
- 每 手 1
- 風險率 4.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alphabet Q3持仓出炉：继续增持头号重仓股SpaceX(SPCX.US) 入股高通(QCOM.US)近5.48亿美元
根据美国证券交易委员会(SEC)披露，谷歌母公司Alphabet(GOOGL.US)提交了截至2026年9月30日的第三季度美股持仓报告(13F)。 据统计，谷...
11-06 21:37
Parabilis Medicines to Participate in Upcoming November Investor Conferences
Parabilis Medicines (PBLS) announced that its leadership team will participate in three investor conferences in November 2026: the Guggenheim Healthcare Innovation Conference in Boston, the Jefferies Global Healthcare Conference in London, and the Evercore ISI Annual Healthcare Conference in Miami. Live webcasts and replays of these events will be available on the company's investor website. Parabilis focuses on developing medicines for serious d...
11-03 12:00
美股大行评级 | 潜在涨幅109.52%！富国银行上调Helus Pharma目标价至22美元，维持"超配"评级
今日重点评级关注：富国银行：维持Helus Pharma"超配"评级，目标价从16美元升至22美元；美银证券：维持SpaceX"买入"评级，目标价从235美元升至275美元
10-23 12:30
HC Wainwright & Co. Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $40
HC Wainwright & Co. initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $40.
10-22 18:54
全球顶级生命科学基金，今年竟拿钱拿到手软？
原标题：全球顶级生命科学基金，今年竟拿钱拿到手软？ 来源：动脉网 动脉网注意到，今年以来，已经有多只生命科学基金完成破纪录募资。 起初是在3月30日，黑石生命...
10-21 13:11
Parabilis Medicines Initiates Dose-Ranging Clinical Cohort Evaluating Zolucatetide In Patients With Familial Adenomatous Polyposis As Part Of Ongoing Phase 1/2 Clinical Trial
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors Zolucatetide directly inhibits β-catenin:TCF, targeting the APC-mutation biology that drives precancerous adenomatous polyp formation in patients...
10-14 19:05
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
Parabilis Medicines has initiated a dose-ranging clinical cohort for zolucatetide in patients with familial adenomatous polyposis (FAP), targeting the β-catenin:TCF interaction. Early data show significant reductions in precancerous polyps, with a favorable safety profile. The study aims to define optimal dosing for future development, addressing a critical unmet need in FAP treatment.
10-14 11:00
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
MeiraGTx Holdings plc announced the appointment of Alan M. Sebulsky to its Board of Directors. With over 40 years of experience in healthcare and biopharmaceutical investment, Sebulsky has led a $2 billion biopharmaceutical portfolio at Adage Capital Management and founded Apothecary Capital. He currently serves on the board of Parabilis Medicines and previously on boards of Jazz Pharmaceuticals and Arrow International. MeiraGTx, a clinical-stage...
09-23 12:00
Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Nasdaq Composite gaining around 400 points on Thursday. Shares of Vicor Corp (NASDAQ:VICR) rose sharply after the company announced it granted a non-exclusive license to a new OEM licensee with the right to procure Vertical Power Delivery modules by its patents from...
09-17 23:58
